Abstract
Lung neuroendocrine tumors (LNETs) are rare cancers subdivided into low-grade (typical) and intermediate-grade (atypical) carcinoids. Atypical carcinoids are more aggressive, with a 4- to 6-fold increased risk of developing metastatic disease and to relapse within the first 10 years after surgical treatment. We performed the first comprehensive molecular characterization of lung carcinoids and identified 3 robust molecular clusters; A1, A2 and B (Alcala, Nature Com., 2019; Gabriel, Gigascience, 2020).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
